Your Article Summary
See Latest ArticlesMeier W et al. - The randomized phase III trial could detect superiority of topotecan versus treosulfan in patients with recurrent disease after platinum–paclitaxel combination therapy. The authors' experience indicates that optimization of systemic treatment could improve outcome even in this poor prognostic subgroup of patients with relapsed ovarian cancer.
Related Articles
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Relevance Score: 72%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%
Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09
Relevance Score: 70%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 70%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 70%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
An alternative monitoring protocol for single-dose methotrexate therapy in ectopic pregnancy
American Journal of Obstetrics and Gynecology, 12/08/09
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/07/09
Correlates of use of antifracture therapy in older women with low bone mineral density
Journal of General Internal Medicine, 12/07/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Revised breast cancer screening guidelines spark uproar, confusion
American Medical News , 12/10/09
Da Vinci S robotic surgery in the treatment of benign and malignant gynecologic tumors
Gynecological Surgery, 12/10/09
Fertility-Sparing Approach in a Teenager with Uterine Tumor Diagnosed as a Sarcoma on Imaging
Gynecologic and Obstetric Investigation, 12/10/09